<SEC-DOCUMENT>0001104659-24-005593.txt : 20240122
<SEC-HEADER>0001104659-24-005593.hdr.sgml : 20240122
<ACCEPTANCE-DATETIME>20240122164506
ACCESSION NUMBER:		0001104659-24-005593
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20240122
FILED AS OF DATE:		20240122
DATE AS OF CHANGE:		20240122

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Evaxion Biotech A/S
		CENTRAL INDEX KEY:			0001828253
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			G7
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39950
		FILM NUMBER:		24549360

	BUSINESS ADDRESS:	
		STREET 1:		DR NEERGAARDS VEJ 5F
		CITY:			HOERSHOLM
		STATE:			G7
		ZIP:			2970
		BUSINESS PHONE:		004531262615

	MAIL ADDRESS:	
		STREET 1:		DR NEERGAARDS VEJ 5F
		CITY:			HOERSHOLM
		STATE:			G7
		ZIP:			2970
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>tm243814d1_6k.htm
<DESCRIPTION>FORM 6-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Washington, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0pt auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM&nbsp;6-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0pt auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>REPORT OF FOREIGN PRIVATE ISSUER</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PURSUANT TO SECTION&nbsp;13a-16 OR 15d-16</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNDER THE SECURITIES EXCHANGE ACT OF 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>For the&nbsp;month of January&nbsp;2024</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Commission File Number: 001-39950</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0pt auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Evaxion Biotech A/S</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(Exact Name of Registrant as Specified in Its
Charter)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0pt auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Dr.&nbsp;Neergaards Vej 5f</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>DK-2970 Hoersholm</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Denmark</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(Address of principal executive offices)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0pt auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">Indicate by check mark whether the registrant files or will
file annual reports under cover of Form&nbsp;20-F or Form&nbsp;40-F.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 245pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Form&nbsp;20-F
</FONT><FONT STYLE="font-family: Wingdings">&#120;</FONT> Form&nbsp;40-F <FONT STYLE="font-family: Wingdings">&#168;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">Indicate by check mark if the registrant is submitting the
Form&nbsp;6-K in paper as permitted by Regulation S-T Rule&nbsp;101(b)(1): <FONT STYLE="font-family: Wingdings">&#168;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">Indicate by check mark if the registrant is submitting the
Form&nbsp;6-K in paper as permitted by Regulation S-T Rule&nbsp;101(b)(7): <FONT STYLE="font-family: Wingdings">&#168;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>INCORPORATION BY REFERENCE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">This report on Form&nbsp;6-K&nbsp;shall
be deemed to be&nbsp;incorporated by reference&nbsp;in Evaxion Biotech A/S&rsquo;s registration statements on&nbsp;Form&nbsp;S-8&nbsp;(File&nbsp;No.&nbsp;333-255064),
on Form&nbsp;F-3 (File No.&nbsp;333-265132) and on Form&nbsp;F-1, as amended (File No.&nbsp;333-266050), including any prospectuses forming
a part of such registration statements and to be a part thereof from the date on which this report is filed, to the extent not superseded
by documents or reports subsequently filed or furnished.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B><I>Press Release</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">On January&nbsp;22, 2024, Evaxion Biotech
A/S (the &ldquo;Company&rdquo;) issued a press release announcing the Company&rsquo;s previously disclosed change to its American Depositary
Share (&ldquo;ADS&rdquo;) to ordinary share ratio has been made effective on January&nbsp;22, 2024. The ratio has changed from one (1)&nbsp;ADS
to one (1)&nbsp;ordinary share to the new ratio of one (1)&nbsp;ADS to ten (10)&nbsp;ordinary shares. A copy of the press release is furnished
as Exhibit&nbsp;99.1 to this report on Form&nbsp;6-K.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify; width: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Exhibit&nbsp;No.</U></B></FONT><B>&nbsp;</B></TD>
  <TD STYLE="text-align: justify"><B><U>Description</U></B></TD></TR>

<TR STYLE="vertical-align: top">
  <TD STYLE="padding-left: 0.2in; text-align: justify; width: 1in"><A HREF="tm243814d1_ex99-1.htm" STYLE="-sec-extract: exhibit">99.1</A></TD>
  <TD STYLE="text-align: justify"><A HREF="tm243814d1_ex99-1.htm" STYLE="-sec-extract: exhibit">Press Release dated January&nbsp;22, 2024.</A></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">Pursuant to the requirements of the Securities Exchange
Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&NegativeThickSpace;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Evaxion Biotech A/S</B></FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&NegativeThickSpace;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&NegativeThickSpace;</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: bottom; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: January&nbsp;22,
    2024</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="vertical-align: top; width: 45%; border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    Christian Kanstrup</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&NegativeThickSpace;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&NegativeThickSpace;</FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name: Christian Kanstrup</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&NegativeThickSpace;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&NegativeThickSpace;</FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title: Chief Executive
    Officer </FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0pt"></P>

<!-- Field: Page; Sequence: 4; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0pt">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>tm243814d1_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><B>Exhibit 99.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Evaxion Announces Completion of ADS Ratio Change</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">COPENHAGEN, Denmark, Jan.&nbsp;22, 2024 (GLOBE
NEWSWIRE) &ndash; Evaxion Biotech A/S (NASDAQ: EVAX) (&ldquo;Evaxion&rdquo; or the &ldquo;Company&rdquo;), a clinical-stage TechBio company
specializing in developing AI-Immunology&trade; powered vaccines,&nbsp;today announced&nbsp;that the Company&rsquo;s previously disclosed
change to its ratio of its American Depositary Shares (&ldquo;ADSs&rdquo;) to its ordinary shares, DKK 1 nominal value (the &ldquo;ADS
Ratio&rdquo;), has been made effective. The ratio has changed from one (1)&nbsp;ADS representing one (1)&nbsp;ordinary share to a new
ADS Ratio of one (1)&nbsp;ADS representing ten (10)&nbsp;ordinary shares (the &ldquo;ADS Ratio Change&rdquo;). The ADS Ratio Change became
effective on January&nbsp;22, 2024 (the &ldquo;Effective Date&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the Company's ADS holders, the change in the
ADS Ratio has the same effect as a one-for-ten reverse ADS split and is intended to further support the liquidity in the Company&rsquo;s
ADSs and to enable the Company to regain compliance with the Nasdaq minimum bid price requirement. The exchange of one (1)&nbsp;new ADS
for every ten (10)&nbsp;then-held (existing) ADSs occurred automatically on the Effective Date, with the then-held ADSs being cancelled
and new ADSs being issued by The Bank of New York Mellon, the depositary bank (the &ldquo;Depositary&rdquo;). Registered holders of the
Company&rsquo;s ADSs held in certificated form were required on a mandatory basis to surrender their certificated ADSs to the Depositary
for cancellation and received one (1)&nbsp;new ADS in exchange for every ten (10)&nbsp;existing ADSs then-held. Holders of uncertificated
ADSs in the Direct Registration System (DRS) and The Depository Trust Company (DTC) had their ADSs cancelled and automatically exchanged,
receiving one (1)&nbsp;new ADS for every ten (10)&nbsp;existing ADS then-held. The Company&rsquo;s ADSs continue to be traded on The Nasdaq
Capital Market under the ticker symbol &ldquo;EVAX&rdquo;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The ADS Ratio Change affects all shareholders
uniformly and will not alter any shareholder&rsquo;s percentage interest in the Company&rsquo;s equity, except to the extent that the
ratio change would have resulted in a shareholder owning fractional ADSs. No fractional new ADSs were issued in connection with the change
in the ADS Ratio. Instead, fractional entitlements to new ADSs will be aggregated and sold by the Depositary, and the net cash proceeds
from the sale of the fractional ADS entitlements (after deduction of fees, taxes and expenses) will be distributed to the applicable ADS
holders by the Depositary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As a result of the ADS Ratio Change, the ADS trading
price is expected to increase proportionally, although the Company can give no assurance that the ADS trading price after the ADS Ratio
Change will be proportionally equal to or greater than the previous ADS trading price prior to the change or that the Ratio Change will
have any effect on the liquidity in the Company&rsquo;s ADSs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>About EVAXION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Evaxion Biotech A/S is a pioneering TechBio company
based upon its AI platform, AI-Immunology&trade;. Evaxion&rsquo;s proprietary and scalable AI prediction models harness the power of artificial
intelligence to decode the human immune system and develop novel immunotherapies for cancer, bacterial diseases and viral infections.
Based upon AI-Immunology&trade;, Evaxion has developed a clinical-stage oncology pipeline of novel personalized vaccines and a preclinical
infectious disease pipeline in bacterial and viral diseases with high unmet medical needs. Evaxion is committed to transforming patients&rsquo;
lives by providing innovative and targeted treatment options. For more information about Evaxion and its groundbreaking AI-Immunology&trade;
platform and vaccine pipeline, please&nbsp;<U>visit our website</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Contact Information</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Evaxion Biotech A/S</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Christian
Kanstrup</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Chief Executive Officer</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>cka@evaxion-biotech.com</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Source: Evaxion Biotech</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><IMG SRC="tm243814d1_ex99-1img01.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Forward-Looking Statement</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This&nbsp;announcement contains forward-looking
statements&nbsp;within the meaning of Section&nbsp;27A of the Securities Act of 1933, as amended, and Section&nbsp;21E of the Securities
Exchange Act of 1934, as amended.&nbsp;The words&nbsp;&ldquo;target,&rdquo; &ldquo;believe,&rdquo; &ldquo;expect,&rdquo; &ldquo;hope,&rdquo;
&ldquo;aim,&rdquo; &ldquo;intend,&rdquo; &ldquo;may,&rdquo; &ldquo;might,&rdquo; &ldquo;anticipate,&rdquo; &ldquo;contemplate,&rdquo;
&ldquo;continue,&rdquo; &ldquo;estimate,&rdquo; &ldquo;plan,&rdquo; &ldquo;potential,&rdquo; &ldquo;predict,&rdquo; &ldquo;project,&rdquo;
&ldquo;will,&rdquo; &ldquo;can have,&rdquo; &ldquo;likely,&rdquo; &ldquo;should,&rdquo; &ldquo;would,&rdquo; &ldquo;could,&rdquo; and
other words and terms of similar meaning&nbsp;identify forward-looking statements.&nbsp;Actual results may differ materially from those
indicated by such forward-looking statements as a result of various factors, including, but not limited to, risks related to: our financial
condition and need for additional capital; our development work; cost and success of our product development activities and preclinical
and clinical trials; commercializing any approved pharmaceutical product developed using our AI platform technology, including the rate
and degree of market acceptance of our product candidates; our dependence on third parties including for conduct of clinical testing and
product manufacture; our inability to enter into partnerships; government regulation; protection of our intellectual property rights;
employee matters and managing growth; our ADSs and ordinary shares,&nbsp;the impact of international economic, political, legal, compliance,
social and business factors, including inflation, and the effects on our&nbsp;business from the worldwide ongoing COVID-19 pandemic and
the ongoing conflict in the region surrounding&nbsp;Ukraine&nbsp;and&nbsp;Russia and the Middle East;&nbsp;and other uncertainties affecting
our business operations and financial condition.&nbsp;For a further discussion of these risks, please refer to the risk factors included
in our most recent Annual Report on Form&nbsp;20-F&nbsp;and other filings&nbsp;with the U.S. Securities and Exchange Commission (SEC),
which are available at&nbsp;<B><U>www.sec.gov</U></B>.&nbsp;We do not assume any obligation to update any forward-looking statements except
as required by law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>tm243814d1_ex99-1img01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm243814d1_ex99-1img01.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  O > # 2(  A$! Q$!_\0
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MHLY!Z'-4-4D:+3[V9"!)!:W,\>X%E\R&"21-P#*2NY02 P)&0",Y'QM^P/\
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M^2C?"GL<$>X(R.^#Q7]G5:Y-_N3_ .PK%_\ IV(\>T\0VMO9TO\ T@*\?O\
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M/NM<TQT;0]<TC4KO3C>-!9R03?:+Z?1OI?XY_MN?LG_LTZMI_AWXY?'7P)X
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MC&G>"M>U--8U;15T"'5X_#%S]KU*-;DZE>Z)<ZO#S!;:A#;?N:?X[^"'PO\
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M]1U>&&6;Q=XLBUOQ<EI;VFEP:[%I5G:64.%XO_X*+_L.>!/B/<?"7Q;^T_\
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M!=/EQ##/;&Q^'6G^$Y;K3)U0Z=KMYK2BWMY)98Q\T7__  ;U?L?7VOW^K?\
M"Q_CS:Z3?ZW=:G_PBEMK?@(:):Z;<:G)?)X;MWE^'\NIC2+:T<:1"\E_)J8L
M5#MJ#7A-S7[OV5E;:?:V]E9V\%I9VD$%K:6MM$L-O:VMM$D%O;00H!'%!!"B
M1Q1HJHB*%4  5Y678'$T*KJXMTVZ=".&H<DI3]R,FY3;DER\R:2BKVVVL=F*
MQ%.I",:*:YYNI5W2YN16>N]Y7VT35^IY[\8OBCX:^"GPM^(WQ<\82^3X8^&?
M@CQ+XZULK)%%-/8>&=)N]6DL;,RD+)J&H-:+8:;;C=)=:C=6MK!'+/-'&W\:
MW_!+O]G2S_X*)?MJ?%/XA_M$:#_PFO@;3-/\9_%WXLZ:]WJMAI.M?$#XH:U?
M6_A+PS-J&BZAINK65B;R^\3^)M'BLM1@3[/X BL9Q<V4\D1_K@_:S_9F\/\
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MN9RLU>F[)16[NUJG\\?\$Y?@[^S_ &/[ _[/FB^"?!/@;7O!WQ'^#/@[7/B
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M;I1E&I%QY4[R4HN-GHXSE=JR,Z=114HR3O%J=*7:;BXR3ZVM9KLTM[L^.O\
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1\RG+VTJ4[:<C5*+7D^9R_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
